Sobi To Start Selling Zynlonta After Sealing EU Approval
High Hopes For Lymphoma Drug
Executive Summary
Five months after paying $55m upfront to Switzerland's ADC Therapeutics, Sobi has been granted conditional marketing authorization for Zynlonta for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
You may also be interested in...
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
ADC’s Label-Expansion Study For Zynlonta Halted For Respiratory Safety
A Phase II study in a frail, older lymphoma population has seen seven respiratory-related deaths along with five other serious adverse events, but so far Zynlonta has been deemed not related to the AEs.
Sobi Maintains Grip On RSV Market – For Now
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.